Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saxagliptin in Cystic Fibrosis
NCT02148978Unknown
- Start
- Mar 2014
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of saxagliptin in cystic fibrosis (CF). Primary endpoint: glucose tolerance after treatment with Saxagliptin at 6 weeks. Status: unknown.
02
Drugs
saxagliptin
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02148978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02148978.